Human amniotic fluid stem cells (hAFSCs) can be grown in large quantities, have a low risk for tumour development and harbour a high differentiation potential. They are a very promising new fetal stem cell type for cell-based therapy approaches and for studying differentiation processes without raising the ethical concerns associated with embryonic stem cells. Recently, a protocol for studies on renal development has been established in which murine embryonic kidneys are dissociated into single-cell suspension and then reaggregated to form organotypic renal structures. Using this approach, we formed chimeric renal structures via mixing murine embryonic kidney cells with monoclonal hAFSCs. We demonstrate here that hAFSCs harbour the potential to contribute to renal tissue formation accompanied by induction of specific renal marker expression. As part of the two kinase complexes mTORC1 and mTORC2, mammalian target of rapamycin (mTOR) is the key component of an important signalling pathway, which is involved in the regulation of differentiation and in the development of a wide variety of human genetic diseases many with characteristic kidney symptoms. Modulating endogenous mTOR activity via specific siRNA approaches revealed that contribution of hAFSCs to renal tissue formation is regulated by mTORC1 and mTORC2. These findings (i) demonstrate renal differentiation potential of hAFSCs, (ii) prove chimeric cultures of mixtures of murine embryonic kidney cells and hAFSCs to be a powerful tool to study the effects of gene knockdowns for renal structure formation and (iii) provide new insights into the role of the mTOR pathway for renal development.
INTRODUCTION
Due to their potential to differentiate into specific lineages, stem cells are optimal models for the detailed investigation of cell differentiation processes and their deregulation during disease development. In addition, much excitement surrounding human stem cells is connected with the hope that they can be a part of new therapeutic strategies for a wide variety of diseases. Whereas the differentiation potential and the proliferative capacity of embryonic stem cells are higher, adult stem cells do not raise ethical concerns and harbour a lower risk of tumour development (1, 2) . In the last years, the discovery of fetal stem cells within human amniotic fluid initiated a new and promising research field. Human amniotic fluid stem cells (hAFSCs) likely represent an intermediate stage between embryonic stem cells and lineage-restricted adult progenitor cells. They might have advantages over embryonic stem cells, such as a lower risk for tumour development and no associated ethical concerns, as well as over adult stem cells, such as the higher proliferation rate and the higher differentiation potential (reviewed in [3] [4] [5] .
Since the first description of cells within the human amniotic fluid expressing the transcription factor Oct4, a marker for pluripotent human stem cells (6) , different stem cell populations with specific differentiation potentials have been described to exist in human amniotic fluid (7 -14) . The relevance of hAFSCs was highlighted by the finding that, descending from a single immunoselected CD117(c-Kit)-positive hAFSC, differentiation along adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic lineages can be induced (15) . Importantly, CD117-selected hAFSCs can be expanded in culture as stable lines with high proliferative capacity (15, 16) . Recently, it was reported that starting from a single hAFSC, which expresses the stem cell markers CD117 and Oct4, embryoid bodies can be formed. * To whom correspondence should be addressed. Tel: +43 1427767500; Fax: +43 142779675; Email: markus.hengstschlaeger@meduniwien.ac.at # The Author 2010. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org These three-dimensional multicellular aggregates allow the recapitulation and investigation of the three-dimensional structure and tissue level contexts of many cell differentiation phenomenons during early mammalian embryogenesis (16) . Familial risks for human genetic diseases are classical indications for amniocenteses. Accordingly, hAFSCs might allow to study specific differentiation processes under normal and pathological conditions. These studies will clarify how the underlying molecular mechanisms are deregulated in cells harbouring natural occurring molecular alterations being causatively involved in the development of specific human genetic diseases (3) .
Recently, a new method was established allowing to study the processes involved in the formation of renal tissues. In this experimental approach, murine embryonic kidneys are dissociated into single-cell suspensions and then reaggregated to form organotypic renal structures. This protocol is a powerful strategy to investigate the ability of stem cells to contribute to renal tissues when placed into a kidney context being of relevance for regenerative medicine. In addition, using this approach, it is possible to modify endogenous gene expression via siRNA-mediated knockdown and to study the consequences for renal structure development (17) . Also recently, we have established a highly efficient and reproducible protocol for prolonged siRNA-mediated gene silencing in hAFSCs (18) .
In mammalian cells, two different mammalian target of rapamycin (mTOR) containing protein kinase complexes, named mTORC1 and mTORC2, are known. mTORC1 consists of the mTOR protein, raptor and mLST8. mTORC2 contains the proteins mTOR, mLST8, rictor and sin1. mTORC1 is involved in the regulation of mRNA translation, for example, via its potential to phosphorylate and activate the kinase p70S6K at T389 to activate the ribosomal protein S6 via phosphorylation at S240/244. mTORC2 phosphorylates Akt at S473, what in conjunction with other phosphorylations drives full activation of Akt. Upstream of mTOR activated receptor tyrosine kinases activate the phosphatidylinositol-3-kinase (PI3K), regulating the activity of Akt. Akt-mediated phosphorylation of tuberin (TSC2) downregulates its GTPase activating potential toward Rheb, which is a potent regulator of mTORC1. This mTOR pathway with its many upstream regulators and downstream targets plays a major role in the regulation of cell differentiation processes and in the development of a wide variety of human genetic diseases many of them with characteristic kidney symptoms (19) (20) (21) (22) (23) .
In the present study, we combined the newly established renal reaggregation assay and the new protocol for prolonged gene silencing in hAFSCs to a powerful tool to provide new insights into the potential of these fetal stem cells and into the underlying mechanisms of renal development. We demonstrate that hAFSCs harbour the ability to contribute to renal structures and we describe this potential to be regulated via mTOR.
RESULTS

Marker expression in CD117-positive hAFSC lines
Approximately 1% of cells in human amniotic fluid are stem cells expressing CD117 (c-Kit) the receptor for stem cell factor. Using immunoselection via magnetic cell sorting, these hAFSCs can be isolated from native human amniotic fluid cell samples obtained via amniocentesis for routine genetic prenatal diagnosis and stem cell lines can be established. The so established hAFSC lines can stably be expanded in culture in an undifferentiated status without need for feeder layers. They harbour the potential to form embryoid bodies and to differentiate into cells of all three embryonic germ layers (15, 16) . Two of such earlier established hAFSC lines, Q1 and CB3, are monoclonal due to minimal dilution approaches. Another CD117-positive hAFSC line, named CD117/2, is not monoclonal.
Recently, a kidney cell reaggregation assay was established allowing to follow the formation of ureteric bud structures and the generation of nephrons (17) . Calbindin is a specific marker for ureteric bud structures (24) and Pax2 expression, being abundant in ureteric bud as well as in nephron structures, is sufficient to specify renal tissue (25) . Immunocytochemical analyses revealed that none of the used hAFSC lines, CD117/2, Q1 and CB3, express calbindin or Pax2 (Figs 1 -3 ).
All three lines express the epithelial markers E-cadherin and laminin, which can also be detected in specific structures of the developing kidney (26, 27) (Figs 1 -3 ). The zinc-finger protein Wt1 is well known to be a major regulator of renal development. siRNA-mediated knockdown of endogenous Wt1 inhibits the formation of nephrons (28) . Immunocytochemical studies demonstrated that CD117/2, Q1 and CB3 cells express Wt1. Wt1 has been demonstrated to be localized to both nucleus and cytoplasm (29) . In our hAFSCs, Wt1 was predominantly cytoplasmic (Figs 1 -3 ). Our observation that the three analysed hAFSC lines express the same pattern of markers and that all analysed cells of each stem cell line were either positive (E-cadherin, laminin, Wt1) or negative (Pax2, calbindin) for the analysed markers demonstrate (i) that this expression pattern is obviously characteristic for hAFSCs, (ii) that the lines Q1, CB3 and CD117/2 behave similarly, (iii) that the growth conditions we use to cultivate hAFSCs do not induce effects on the expression of these markers, for example, caused by differentiation processes.
Taken together, these data show that all analysed hAFSCs do not express proteins, such as calbindin and Pax2, which are specific for differentiated renal structures, but are positive for the protein Wt1, what is of highest relevance for the potential for specific renal differentiation.
hAFSCs can contribute to the formation of specific renal tissue
Next we wanted to investigate whether hAFSCs can contribute to renal structures making use of the above-mentioned reaggregation assay. We planned to dissociate mouse embryonic kidneys into single cells, mix them with CellTracker-stained hAFSCs and let these chimeric cultures develop on a filter (compare the schematic diagram in Fig. 4 ). At this step, it was important to clarify that CellTracker treatment alone does not affect hAFSCs. Immunocytochemical analyses revealed that the pattern of protein marker expression was not altered in hAFSCs upon CellTracker staining (Figs 1 -3) . by the detection of cells with subG1 DNA content), cell size (forward scatter analyses) or cell morphology (microscopical analysis) of hAFSCs (Fig. 5 ).
Using the dissaggregation -reaggregation approach presented in Fig. 4 , we were able to produce fine-grained chimeric renal tissues composed of unlabelled murine embryonic kidney cells and of labelled hAFSCs (Figs 6 and 7) . Upon this chimeric cultivation, we detected CellTracker (green)-stained hAFSCs within the structures expressing the renal specific marker Pax2 (known to be expressed in ureteric bud and nephron structures), E-cadherin (known to be found in distal tubule), calbindin (specific for the ureteric bud), Wt1 (high abundant in glomerular pole) and laminin (a marker for epithelial structures in the developing kidney) (Figs 6 and 7) (for the literature of the mentioned marker specificities, see 17, [24] [25] [26] [27] [28] . Laminin is a secreted protein (27) . Although we found hAFSCs to express laminin under normal cultivation conditions (Figs 1 -3 ), in the chimeras it is difficult to clarify whether the detected laminin is produced by hAFSCs or by the mouse cells that they face. As already mentioned, Wt1 has been demonstrated to be localized to both nucleus and cytoplasm. This localization is regulated via different mechanisms and might vary in different cell types (29 and references therein). Wt1 was predominantly cytoplasmic in hAFSCs cultivated under normal growth conditions (Figs 1-3) . It appeared that in the reaggregation assay hAFSCs with nuclear, but in most cases with cytoplasmic Wt1, could be detected. Further investigations are warranted to clarify whether this observed Wt1 localization plays a specific role for the differentiation potential of hAFSCs or, in the here used 
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Human Molecular Genetics, 2010, Vol. 19, No. 17 assay, represents a specific differentiation status. Since Wt1 and Pax2 have also been reported to be markers for metanephric mesenchyme, our data suggest that hAFSCs can also contribute to other renal structures than, for example, ureteric bud cells. However, the fact that in many reports, nuclear Wt1 was defined as such a marker (28,29 and references therein), our finding of also cytoplasmic Wt1 again highlights the importance of further investigations. Importantly, our findings demonstrate that hAFSCs, originally not expressing Pax2 and calbindin, harbour the potential to contribute to renal tissue formation accompanied by the induction of the expression of the renal specific markers Pax2 and calbindin.
The role of tuberin for the potential of hAFSCs to contribute to renal structures
The mTOR signalling cascade with its many upstream regulators and downstream targets plays a central role in the regulation of growth, tumour development and cell differentiation processes (19, (21) (22) (23) . However, data regarding the role of mTOR in the regulation of renal cells are limited and mainly obtained from studies using chemical inhibitors, such as rapamycin (30) (31) (32) . To investigate the question whether specific components of the mTOR pathway are involved in the regulation of hAFSC contribution to renal structures, we decided to combine the recently published kidney reaggregation assay (17) with the also recently established protocol for prolonged siRNA-mediated gene silencing in hAFSCs (18) . The latter allows the siRNA-mediated knockdown of endogenous gene products in hAFSCs for at least 14 days. We planned to downregulate specific endogenous gene functions in hAFSCs via siRNA approaches and to quantify the effects of this modulation on stem cell contribution to renal structures (compare the schematic presentation in Fig. 8 ).
Tuberin, encoded by the tumour suppressor gene TSC2, is a major negative upstream regulator of mTOR known to be expressed in renal tissue (33) . Mutations in TSC2 cause the autosomal dominant disease tuberous sclerosis, which is characterized by the development of hamartomas in different organs including kidney (20, 23) . TSC2-specific siRNA experiments triggered over 90% downregulation of endogenous tuberin expression in monoclonal hAFSCs ( Fig. 9A and B) . Interestingly, this downregulation was accompanied by only weak effects on endogenous phosphorylation of S6, which is a substrate of the mTORC1-regulated p70S6K (see Introduction) (Fig. 9A) . We then tested whether Q1 stem cells with downregulated tuberin expression have the same potential to integrate into renal structures as control Q1 cells. Although statistical analyses did not demonstrate significance, the observed trend of induced stem cell contribution would support the notion that mTOR is a positive regulator of this process (Fig. 9C) . To clarify whether mTOR really plays a role for the potential of hAFSCs to contribute to renal structures, we directly targeted endogenous mTOR protein via specific siRNAs. Downregulation of mTOR protein expression in hAFSCs triggered a decrease of the p70S6K-mediated phosphorylation of endogenous S6 protein ( Fig. 10A and B) . The percentage of areas of mTOR-specific siRNA-treated CellTracker-labelled hAFSCs (44.7%) was significantly (P ≤ 0.05) diminished compared with control siRNA-treated hAFSCs (set to 100%) ( Figs 10C and 11 ). These findings demonstrate mTOR to be of importance for the potential of hAFSCs to contribute to renal tissue formation.
The role of mTORC1 and mTORC2 for the potential of hAFSCs to contribute to renal tissue formation
As mentioned earlier, the question whether mTOR affects renal tissue formation remained elusive so far. In addition, the limited data, for example, regarding the role of mTOR for renal fibroblast proliferation were obtained from studies using chemical inhibitors, such as rapamycin (30) (31) (32) . The mTOR protein forms two complexes, mTORC1 and mTORC2, which harbour different substrate specificities. Rapamycin, bound to the protein FKBP12, generates a drug-receptor complex that binds and inhibits mTORC1. Since FKBP12-rapamycin does not bind to preformed mTORC2, rapamycin was originally thought to only inhibit mTORC1 (19, 21, 22) . However, recent findings provided evidence that rapamycin also suppresses the function of mTORC2 (34, 35) . The data obtained with mTOR-specific siRNAs made it important to further clarify whether mTORC1, mTORC2 or both kinase complexes are involved in the regulation of hAFSC contribution to renal tissue formation. First, we performed siRNA experiments to downregulate the endogenous protein levels of the mTORC1-specific component raptor in hAFSCs. Western blot analyses showed that raptor-specific siRNA treatment caused a pronounced downregulation of both endogenous raptor protein levels and mTORC1-mediated p70S6K T389 phosphorylation ( Fig. 12A  and B) . The ability of so treated hAFSCs to contribute to renal tissues in the kidney reaggregation assays was decreased to 31.4% compared with cells treated with control siRNAs (P ≤ 0.05; Fig. 12C ; compare also Fig. 11) .
The siRNA-mediated knockdown of rictor caused a downregulation of the endogenous amount of phosphorylated Akt S473, which is a substrate of mTORC2 ( Fig. 13A and B) . The percentage of areas of rictor-specific siRNA-treated CellTracker-labelled hAFSCs (21.2%) was significantly (P ≤ 0.05) lower compared with control siRNA-treated hAFSCs (set to 100%) ( Fig. 13C ; compare also Fig. 11 ). Taken together, these data demonstrate (i) that mTOR is an important regulator of the potential of hAFSCs to contribute to renal tissue formation, and (ii) that mTOR is mediating its effects via both mTOR containing kinase complexes, mTORC1 and mTORC2.
DISCUSSION
Chronic renal disorders often result from congenital malformations, diabetes, chronic infections, autoimmune diseases 
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or hypertension, whereas acute renal failure can be the consequence of sepsis, hypothermia or trauma. For renal transplantations, the shortage of compatible organs is the limiting factor and the mortality rate of patients requiring chronic renal dialysis is high. Consequently, the putative usage of stem cells in the repair of kidney injury is currently under intensive investigation (2, 36) . Due to these drawbacks of dialysis and transplantation, stem cell-based therapies are of special (38, 39) . Additionally, CD133-positive progenitor cells, expressing the renal marker Pax2, have been isolated from adult human kidneys (40) . These adult stem cells might represent potent resident cell populations that could contribute to the repair of renal injury. An important aspect for the future will be to clarify whether they can efficiently and stably be expanded in vitro, as it is possible for embryonic stem cells. On the other hand, the usage of embryonic stem cells for renal therapies is constrained by the risk of malignant development, by the immunological rejection as well as by ethical considerations. However, embryonic stem cells have already been proven to be able to undergo renal differentiation and it has also been demonstrated that embryonic stem cells transplanted into kidney rudiments ex vivo can give rise to proximal tubular cells and can integrate into the glomerular tufts (41, 42) .
hAFSCs representing a fetal intermediate stage between embryonic and adult stem cells are a new promising source for both regenerative medicine and basic research. Regarding accessibility, the risk for malignant development and ethical considerations, they might have advantages over embryonic stem cells. Higher proliferation rates and multipotentiality are their advantages when compared with adult stem cells (reviewed in 3,4). It has already been reported earlier that (A) Q1 stem cells were transfected with non-specific control siRNAs, or siRNAs specific for TSC2. Seventy-two hours after transfection, total protein lysates were used to prove downregulation of endogenous tuberin via western blot analyses. In addition, the amount of phosphorylated S6 S240/244, which is a substrate of the mTORC1-regulated p70S6Kinase, has been analysed. Detection of a-tubulin was included to prove equal loading of lysates. (B) Bands for tuberin and a-tubulin of several experiments performed as presented in (A) were densitometrically analysed. So obtained tuberin levels were normalized to a-tubulin levels and the effects of siRNAmediated knockdown on endogenous tuberin are presented as percentage of the control experiments set to 100% (+SEM). (C) Q1 stem cells treated as described in (A) were used in renal tissue aggregation assays (as presented in Fig. 4 ) and areas of TSC2-siRNA-treated Q1 stem cell contribution to renal structures (microscopically quantified as presented in Fig. 8 ) are given as percentage of the control experiments set to 100% (+SEM).
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hAFSCs can integrate into existing renal tissues within whole organs when microinjected into isolated murine embryonic kidneys (13) . In addition, a potential for renal differentiation has been suggested by our finding that the expression of specific renal markers (analysed via RT-PCR) can be induced in hAFSCs via cultivation with epidermal growth factor/platelet-derived growth factor and fibroblast growth factor-4/hepatocyte growth factor (43) . In this study using a monoclonal hAFSC line generated by minimal dilution approaches, we demonstrate that descending from one single cell hAFSCs are able to contribute to the formation process of renal tissues. This process is accompanied by the induction of the expression of well-known renal markers in hAFSCs. These results prove that the earlier described kidney reaggregation assay (17) can be used to form fine-grained chimeric renal tissues composed of embryonic kidney cells and hAFSCs. Furthermore, we provide evidence for the renal differentiation potential of hAFSCs. It is tempting to speculate that hAFSCs could once be considered as a new promising source for cell-based therapies to repair kidney injury. On the other hand, this approach could be useful to assess the cell autonomy of naturally occurring disease-causing mutations. Worldwide, amniocenteses are performed for prenatal genetic diagnosis of monogenetic diseases. It could be Figure 10 . mTOR positively regulates the contribution of hAFSCs to renal tissues. (A) Monoclonal Q1 stem cells were transfected with non-specific control siRNAs, or siRNAs specific for mTOR. Seventy-two hours after transfection, total protein lysates were used to prove downregulation of endogenous mTOR via western blot analyses. In addition, the amount of phosphorylated S6 S240/244, which is a substrate of the mTORC1-regulated p70S6Kinase, has been analysed. Detection of a-tubulin was included to prove equal loading of lysates. (B) Bands for mTOR and a-tubulin of different experiments performed as presented in (A) were densitometrically analysed. So obtained mTOR levels were normalized to a-tubulin levels and the effects of siRNAmediated knockdown on endogenous mTOR are presented as percentage of the control experiments set to 100% (+SEM). (C) Q1 stem cells treated as described in (A) were used in renal tissue aggregation assays (as presented in Fig. 4 ) and areas of mTOR-siRNA-treated Q1 stem cell contribution to renal structures (microscopically quantified as presented in Fig. 8 ) are given as percentage of the control experiments set to 100% (+SEM). with non-specific control siRNAs, or siRNAs specific for raptor. Seventy-two hours after transfection, total protein lysates were used to prove downregulation of endogenous raptor via western blot analyses (the asterisk indicates an unspecific band). In addition, the amount of phosphorylated p70S6K T389, which is a substrate of mTORC1, has been analysed. Detection of a-tubulin was included to prove equal loading of lysates. (B) Bands for raptor and a-tubulin of several experiments performed as presented in (A) were densitometrically analysed. So obtained raptor levels were normalized to a-tubulin levels and the effects of siRNA-mediated knockdown on endogenous raptor are presented as percentage of the control experiments set to 100% (+SEM). (C) Q1 stem cells treated as described in (A) were used in renal tissue aggregation assays (as presented in Fig. 4 ) and areas of raptor-siRNA-treated Q1 stem cell contribution to renal structures (microscopically quantified as presented in Fig. 8 ) are given as percentage of the control experiments set to 100% (+SEM).
Human
of highest relevance for basic research to establish clonal hAFSC lines derived from pregnancies with specific genetic aberrations and to test the relevance of these mutations for the potential to contribute to renal tissue formation. This will be a powerful approach to recapitulate normal and pathological differentiation processes in vitro without the need of prior processing to induce stem cell properties as necessary in case of induced pluripotent stem cells (3, 44) . Upstream regulators of mTOR, such as Wnt, TNF-a, Ras, PI3K, Akt and Rheb are known to be deregulated in many human cancers including renal carcinomas. In addition, mutations in the mTOR pathway component genes TSC1, TSC2, LKB1, PTEN, VHL, NF1 and PKD1 trigger the development of the human genetic syndromes Tuberous sclerosis, Peutz -Jeghers syndrome, Cowden syndrome, BannayanRiley -Ruvalcaba syndrome, Lhermitte -Duclos disease, Proteus syndrome, von Hippel-Lindau disease, Neurofibromatosis type 1 and Polycystic kidney disease, many of them with characteristic kidney symptoms (20, 23) . In this study, we made use of two recently established protocols, the kidney reaggregation assay (17) and prolonged siRNAmediated gene knockdown in hAFSCs (18) , to investigate the role of mTOR components on the potential of hAFSCs to contribute to renal tissue formation. The obtained results proved that this combination is an efficient and reproducible approach to study the effects of modulating endogenous gene expression on specific stem cell properties. We observed a trend for increased renal tissue contribution in hAFSCs upon downregulation of the negative upstream mTOR regulator tuberin. The fact that these effects were not proven to be statistically significant might be explained by the only low effects on the mTOR-regulated S6 phosphorylation under these experimental conditions. However, directly targeting endogenous mTOR protein expression via specific siRNAs clearly demonstrated that this kinase is an important regulator of renal tissue formation of hAFSCs. In mammalian cells, two different mTOR complexes, mTORC1 and mTORC2, with different protein components and different target specificities have been described (19, 21, 22) . Experiments to knockdown the endogenous expression of the mTORC1-specific component raptor and of the mTORC2-specific component rictor revealed that mTOR can mediate these effects via both mTOR-containing intracellular kinase complexes. Besides its effects on cell differentiation processes, mTOR is also known to play a role for cell proliferation and apoptosis (21 -23) . For our here reported effects of modulated mTOR activity on the amount of hAFSCs integrated into renal structures, mTOR's potential to regulate proliferation very likely does not play a role. In the course of the dissaggregationreaggregation assays performed, the cells do not perform rounds of cell division within the analysed time periods. Accordingly, regulating proliferation cannot trigger the observed effects. This notion is additionally supported by our observation that modulating mTOR affects the distribution of hAFSCs rather than the total amount of hAFSCs in these assays. Although this finding also suggests that regulation of cell survival is not dominantly involved, further investigations are warranted to separate all different potentials of mTOR with respect to their role in affecting renal structure formation in the experimental setting used.
The so far reported only limited data, for example, regarding the role of mTOR for renal fibroblast proliferation were obtained from studies using chemical inhibitors, such as rapamycin, not allowing to separate mTORC1-specific effects from effects of mTORC2 (30) (31) (32) . To our knowledge, this is the first description of a role of mTOR in the process of renal tissue formation. Downstream of mTOR there are many known targets, which putatively could be involved in this regulation. For a better understanding of the role of mTOR in renal development and for the putative establishment of new therapeutic strategies for renal failures, it could be of importance to identify relevant downstream components in future work.
MATERIALS AND METHODS
Cells, cell culture and flow cytometry
The two hAFSC lines CB3 (monoclonal) and CD117/2 (not monoclonal) were already established earlier through magnetic cell sorting by using the CD117 MicroBead Kit (Miltenyi Biotec, Bergisch Gladbach, Germany, 130-091-332) (16) . The monoclonal hAFSC line Q1 has also been established earlier using the same protocol as described above (15) . The cells Figure 13 . The mTORC2 component rictor affects the contribution of hAFSCs to renal tissues. (A) Monoclonal Q1 hAFSCs were transfected with non-specific control siRNAs, or siRNAs specific for rictor. Seventy-two hours after transfection, total protein lysates were used to prove downregulation of endogenous rictor via western blot analyses. In addition, the amount of phosphorylated Akt S473, which is a substrate of mTORC2, has been analysed. Detection of a-tubulin was included to prove equal loading of lysates. (B) Bands for rictor and a-tubulin of several experiments performed as presented in (A) were densitometrically analysed. So obtained rictor levels were normalized to a-tubulin levels and the effects of siRNA-mediated knockdown on endogenous rictor are presented as percentage of the control experiments set to 100% (+SEM). (C) Q1 stem cells treated as described in (A) were used in renal tissue aggregation assays (as presented in Fig. 4 ) and areas of rictor-siRNA-treated Q1 stem cell contribution to renal structures (microscopically quantified as presented in Fig. 8 ) are given as percentage of the control experiments set to 100% (+SEM).
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Human Molecular Genetics, 2010, Vol. The room was illuminated with artificial light at an intensity of about 200 lx in 2 m from 5 am to 7 pm. Matings were setup and mice pregnant at day 11.5 were sacrificed by cervical dislocation. The uteri of the mice were prepared and the embryos were sacrificed by decapitation immediately after isolation. The kidney rudiments of the E11.5 mouse embryos were dissected and trypsinated as described (17) . The obtained single cell suspension was divided into 500 ml tubes, each containing 9 × 10 4 cells on average.
CellTracker staining
Stem cells were harvested and stained in a solution of 4 mmol/l CellTracker Green (Molecular Probes-Invitrogen, C2925) in minimum essential eagles medium (Sigma-Aldrich, M5650) for 40 min at 378C and 5% CO 2 . The stained cells were washed in minimum essential eagles medium containing 10% FCS. The stained cells were either seeded onto glass slides for immunostaining or brought into pellets for further culture.
Pellet formation and culture 1 × 10 4 CellTracker-stained hAFSCs were mixed with 9 × 10 4 embryonic kidney cells in a 500 ml tube. The cell mixture was then centrifuged at 800 g for 2 min to form a pellet at the bottom of the tube. The pellet was carefully detached using a 200 ml pipette and placed gently onto a 5 mm pore polycarbonate filter (Millipore, Billerica, MA, USA, TMTP02500) using a glass pasteur pipette. This filter was supported by a metal grid at the medium-air interface (46) . The culture medium was minimum essential eagles medium supplemented with 2% FCS, 50 mg/l streptomycin sulphate and 30 mg/l penicillin. The pellets were cultured for 4 days at 378C, 5% CO 2 . For the first 24 h of culture, the medium was supplemented with the ROCK-Inhibitor Glycyl-H1152 dihydrochloride (Tocris, Ellisville, MO, USA, 2485) (17) .
Imaging and quantification of stem cell contribution to renal structures
All samples were analysed either on a Leica TCS NT confocal microscope (Leica Microsystems, Buckinghamshire, UK) or on a Zeiss LSM Exciter confocal microscope (Cal Zeiss, Oberkochen, Germany). The microscopes were not changed within one experiment. The confocal sections were analyzed with the software Cell^D (Olympus, Tokyo, Japan). For quantification of CellTracker-labelled hAFSCs integrated into newly formed nephron and ureteric bud structures, we analyzed 10 randomly chosen frames per condition. The area of laminin enclosed structures was determined using the microscopic imaging software Cell^D. The frames analyzed included an average of nine structures per frame. The area of CellTracker positive cells (green) within these structures was determined by the same procedure and the percentage of integrated areas (green) in relation to the total area was quantified (compare Fig. 8 ).
siRNA treatment RNA silencing was achieved with siRNA specific for tuberin, mTOR, raptor or rictor (Dharmacon, Lafayette, CO, USA, L-003029, L-004107, L-016984, L-003008) at a final concentration of 50 nM. The siRNA was delivered to the cells with the RNAiMAX reagent (Invitrogen, 13778075). A pool of four nontargeting siRNAs was used as a control for non-sequence-specific effects for each transfection (18) .
Protein extraction
Total protein was extracted by physical disruption of cell membranes by repeated freeze -thaw cycles. Cells were washed with PBS and harvested by trypsin incubation. Pellets were lysed in buffer A containing 20 mM Hepes, 
